AIM ImmunoTech Inc (AIMID)

Currency in USD
9.250
+0.595(+6.87%)
Closed·
Showing AIM ImmunoTech historical data. For real-time data please try another search
Day's Range
8.5049.250
52 wk Range
2.51039.990
Key Statistics
Prev. Close
6.7
Open
8.916
Day's Range
8.504-9.25
52 wk Range
2.51-39.99
Volume
8.59K
Average Volume (3m)
7.03K
1-Year Change
-76.52%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock

AIM ImmunoTech Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Neutral

AIM ImmunoTech Inc Company Profile

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. The company is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

AIM ImmunoTech Inc Earnings Call Summary for Q4/2024

  • Q4 2024 revenue up 27% YoY to $127.2M; net loss narrowed to $42.1M, improving by $17.8M
  • Bizetto and Cortland drove growth; EPS missed forecast (-$0.10 vs -$0.09); stock fell 5.47% premarket
  • 2025 adjusted EBITDA guidance: $88M-$95M; aim to reduce HoldCo costs below $11M
  • Exploring capital allocation strategies; geopolitical tensions and profitability remain key challenges
  • InvestingPro rates financial health as WEAK (1.35); stock down 72.85% over past year
Last Updated: 28/03/2025, 14:34
Read Full Transcript

Earnings

Latest Release
Aug 15, 2025
EPS / Forecast
-3.68 / -0.08
Revenue / Forecast
25.00K / 100.00K
EPS Revisions
Last 90 days

AIMID Income Statement

People Also Watch

2.35
INMB
-0.42%
20.06
SRPT
-2.53%
2.170
VOR
-1.36%
0.0806
OP
-20.98%
6.9800
UPXI
-0.99%
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.